Skip to Content
  • Previous Rank51
  • Revenues ($M)49,605
  • Revenue Percent Change-7.8%
  • Profits ($M)9,135
  • Profits Percent Change-58.5%
  • Market Value (as of March 31, 2015)213,622

Sales dropped and profit plummeted for Pfizer in 2014 due to the strong dollar and loss of patent protection for drugs like Celebrex, the blockbuster pain medication, and Viagra. The pharma giant made several unsuccessful bids to get bigger—and land a tax-lowering inversion deal—by buying a competitor, first courting big, British AstraZeneca and then Ireland’s Actavis. Left to its own portfolio and pipeline for now, the company did well by a number of drugs including Lyrica, its fibromyalgia med and its Prevnar vaccine, and is optimistic about oncology drugs coming down its pipeline.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Ian C. Read
Industry
Pharmaceuticals
Sector
Health Care
HQ Location
New York, NY
Websitehttp://www.pfizer.com
Years on List21

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)49,605-7.8%
Profits ($M)9,135-58.5%
Total Stockholder Equity71,301-
Employees78,300-
Market Value (as of March 31, 2015)213,622-

Profit Ratios

Profit as % of Revenues18.4%
Profits as % of Assets5.4%
Profits as % of Stockholder Equity12.8%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)1.42
EPS % Change (from 2013)-55.5%
EPS % Change (5 year annual rate)2.9%
EPS % Change (10 year annual rate)-0.5%

Total Return

Total Return to Investors (2014)5.2%
Total Return to Investors (5 year, annualized)15.7%
Total Return to Investors (10 year, annualized)5.9%